SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Corporation Release: Hepatitis C: Interferon-free Combination of BI 201335 Plus BI 207127 and ribavirin Shows up to 76% of Patients Achieve a Virological Response at Week 12, and 59% Achieve SVR12 with 16 Weeks Treatment 1